Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
about
Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsAnti-angiogenic agents in metastatic colorectal cancerImpact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts.Emerging tyrosine kinase inhibitors for the treatment of renal cancer.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I studyFamitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.Emerging drugs for the treatment of gastrointestinal stromal tumour.New targets and therapies for gastrointestinal stromal tumors.Latest advances in adult gastrointestinal stromal tumors.Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
P2860
Q26799387-DF8EA8F9-F4E4-44FC-9DFA-FFF8594A38B7Q26801911-CB75F219-60AB-4801-80C4-5EFA43BBAEFFQ36720067-006020D8-ED49-42C7-8F43-6B89A0C1A776Q37204806-AF9EA194-FD5E-4564-BD24-F88C065A77AEQ38485779-298202D8-D87E-40F5-BEAC-5BA44670E4D9Q38759141-C3CE7140-6FAF-441B-A60F-3570842C4C09Q38794338-214A027E-9CFD-4B95-8D3C-D5087CAA886AQ38838220-D3BAD3D3-5186-4145-8FC4-BAABB091FCB8Q38864184-B0A048FE-7FB5-4EDC-85FC-61BE6D333C87Q38925022-8EDE9843-CC98-40DD-A099-CC9E03799CCCQ38979882-9B06E6A5-DA72-4B8C-BF0A-46185CA1F2ACQ47104695-C04FCE73-588A-42D5-9A1F-5338D1CB63EBQ47355982-11B0283A-6332-41FB-A628-A28043D91E86Q47432725-8CA969EF-F040-44B9-B037-B0B364923046Q47912361-4F70485F-367F-402F-96CD-2603FCD9FFC5Q54344097-D13A324F-0308-4112-B237-C30F689D07CA
P2860
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
@en
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
@nl
type
label
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
@en
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
@nl
prefLabel
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
@en
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
@nl
P2093
P2860
P1476
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
@en
P2093
Aiping Zhou
Chunxiao Chang
Dafang Zhong
Donghua Lou
Haoyuan Jiang
Jinwan Wang
Xiaoyan Chen
P2860
P2888
P304
P356
10.1007/S00280-013-2282-Y
P577
2013-09-17T00:00:00Z